Pluristem Company

Pluristem Therapeutics Inc. is a clinical-stage biotechnology company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases. Pluristem derives its cell products from human placental cells. These cells are converted into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues. Pluristem’s pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease.
Technology: 3D Technology, Biotechnology, Therapeutics
Industry: Regenerative Medicine
Headquarters: Haifa, Israel
Founded Date: 2003
Employees Number: 50-250
Funding Status: IPO

Visit Website
Register and Claim Ownership